Cargando…

Central pontine myelinolysis during treatment of hyperglycemic hyperosmolar syndrome: a case report

BACKGROUND: Central pontine myelinolysis (CPM) is a non-inflammatory demyelinating lesion of the pons. CPM and extrapontine demyelination (EPM) are together termed osmotic demyelination syndrome (ODS), a known and serious complication of acute correction of hyponatremia. Conversely, hyperglycemic hy...

Descripción completa

Detalles Bibliográficos
Autores principales: Kusumoto, Koshi, Koriyama, Nobuyuki, Kojima, Nami, Ikeda, Maki, Nishio, Yoshihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7667752/
https://www.ncbi.nlm.nih.gov/pubmed/33292743
http://dx.doi.org/10.1186/s40842-020-00111-6
_version_ 1783610375066877952
author Kusumoto, Koshi
Koriyama, Nobuyuki
Kojima, Nami
Ikeda, Maki
Nishio, Yoshihiko
author_facet Kusumoto, Koshi
Koriyama, Nobuyuki
Kojima, Nami
Ikeda, Maki
Nishio, Yoshihiko
author_sort Kusumoto, Koshi
collection PubMed
description BACKGROUND: Central pontine myelinolysis (CPM) is a non-inflammatory demyelinating lesion of the pons. CPM and extrapontine demyelination (EPM) are together termed osmotic demyelination syndrome (ODS), a known and serious complication of acute correction of hyponatremia. Conversely, hyperglycemic hyperosmolarity syndrome (HHS) develops in patients with type 2 diabetes who still have some insulin secretory ability due to infection, non-compliance with treatment, drugs, and coexisting diseases, and is often accompanied by ketosis. HHS represents a life-threatening endocrine emergency (mortality rate, 10–50%) associated with marked hyperglycemia and severe dehydration. HHS may develop ODS, and some cases have been associated with hypernatremia. CASE PRESENTATION: The patient was an 87-year-old woman with hyperglycemia, dehydration, malnutrition, and potential thrombus formation during long-term bed rest. HHS was suspected to have developed due to progression of hyperglycemia and dehydration caused by pneumonia. Furthermore, ketoacidosis developed from ketosis and prerenal renal failure associated with circulating hypovolemia shock, which was also associated with disseminated intravascular coagulation. Treatment was started with continuous intravenous injection of fast-acting insulin and low-sodium replacement fluid. In addition, ceftriaxone sodium hydrate, heparin sodium, thrombomodulin α, human serum albumin, and dopamine hydrochloride were administered. Blood glucose, serum sodium, serum osmolality, and general condition (including vital, infection/inflammatory findings, and disseminated intravascular coagulation) improved promptly, but improvements in disturbance of consciousness were poor. Diffusion-weighted imaging of the brain 72 h after starting treatment showed no obvious abnormalities, but high-intensity signals in the midline of the pons became apparent 30 days later, leading to definitive diagnosis of CPM. CONCLUSIONS: Fluctuation of osmotic pressure by treatment from hyperosmolarity due to hyperglycemia and hypernatremia in the presence of risk factors such as malnutrition, severe illness, and metabolic disorders may be a cause of CPM onset. When treating HHS with risk factors, the possibility of progression to ODS needs to be kept in mind.
format Online
Article
Text
id pubmed-7667752
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-76677522020-11-17 Central pontine myelinolysis during treatment of hyperglycemic hyperosmolar syndrome: a case report Kusumoto, Koshi Koriyama, Nobuyuki Kojima, Nami Ikeda, Maki Nishio, Yoshihiko Clin Diabetes Endocrinol Case Report BACKGROUND: Central pontine myelinolysis (CPM) is a non-inflammatory demyelinating lesion of the pons. CPM and extrapontine demyelination (EPM) are together termed osmotic demyelination syndrome (ODS), a known and serious complication of acute correction of hyponatremia. Conversely, hyperglycemic hyperosmolarity syndrome (HHS) develops in patients with type 2 diabetes who still have some insulin secretory ability due to infection, non-compliance with treatment, drugs, and coexisting diseases, and is often accompanied by ketosis. HHS represents a life-threatening endocrine emergency (mortality rate, 10–50%) associated with marked hyperglycemia and severe dehydration. HHS may develop ODS, and some cases have been associated with hypernatremia. CASE PRESENTATION: The patient was an 87-year-old woman with hyperglycemia, dehydration, malnutrition, and potential thrombus formation during long-term bed rest. HHS was suspected to have developed due to progression of hyperglycemia and dehydration caused by pneumonia. Furthermore, ketoacidosis developed from ketosis and prerenal renal failure associated with circulating hypovolemia shock, which was also associated with disseminated intravascular coagulation. Treatment was started with continuous intravenous injection of fast-acting insulin and low-sodium replacement fluid. In addition, ceftriaxone sodium hydrate, heparin sodium, thrombomodulin α, human serum albumin, and dopamine hydrochloride were administered. Blood glucose, serum sodium, serum osmolality, and general condition (including vital, infection/inflammatory findings, and disseminated intravascular coagulation) improved promptly, but improvements in disturbance of consciousness were poor. Diffusion-weighted imaging of the brain 72 h after starting treatment showed no obvious abnormalities, but high-intensity signals in the midline of the pons became apparent 30 days later, leading to definitive diagnosis of CPM. CONCLUSIONS: Fluctuation of osmotic pressure by treatment from hyperosmolarity due to hyperglycemia and hypernatremia in the presence of risk factors such as malnutrition, severe illness, and metabolic disorders may be a cause of CPM onset. When treating HHS with risk factors, the possibility of progression to ODS needs to be kept in mind. BioMed Central 2020-11-16 /pmc/articles/PMC7667752/ /pubmed/33292743 http://dx.doi.org/10.1186/s40842-020-00111-6 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Case Report
Kusumoto, Koshi
Koriyama, Nobuyuki
Kojima, Nami
Ikeda, Maki
Nishio, Yoshihiko
Central pontine myelinolysis during treatment of hyperglycemic hyperosmolar syndrome: a case report
title Central pontine myelinolysis during treatment of hyperglycemic hyperosmolar syndrome: a case report
title_full Central pontine myelinolysis during treatment of hyperglycemic hyperosmolar syndrome: a case report
title_fullStr Central pontine myelinolysis during treatment of hyperglycemic hyperosmolar syndrome: a case report
title_full_unstemmed Central pontine myelinolysis during treatment of hyperglycemic hyperosmolar syndrome: a case report
title_short Central pontine myelinolysis during treatment of hyperglycemic hyperosmolar syndrome: a case report
title_sort central pontine myelinolysis during treatment of hyperglycemic hyperosmolar syndrome: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7667752/
https://www.ncbi.nlm.nih.gov/pubmed/33292743
http://dx.doi.org/10.1186/s40842-020-00111-6
work_keys_str_mv AT kusumotokoshi centralpontinemyelinolysisduringtreatmentofhyperglycemichyperosmolarsyndromeacasereport
AT koriyamanobuyuki centralpontinemyelinolysisduringtreatmentofhyperglycemichyperosmolarsyndromeacasereport
AT kojimanami centralpontinemyelinolysisduringtreatmentofhyperglycemichyperosmolarsyndromeacasereport
AT ikedamaki centralpontinemyelinolysisduringtreatmentofhyperglycemichyperosmolarsyndromeacasereport
AT nishioyoshihiko centralpontinemyelinolysisduringtreatmentofhyperglycemichyperosmolarsyndromeacasereport